Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients

Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients

(2019) Tucker Coston et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management

(2018) Mrinal M. Patnaik et al.   AMERICAN JOURNAL OF HEMATOLOGY

Consequences of mutant TET2 on clonality and subclonal hierarchy

(2018) Cassandra M. Hirsch et al.   LEUKEMIA

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

(2018) Matthieu Duchmann et al.   EBioMedicine

Functional genomic landscape of acute myeloid leukaemia

(2018) Jeffrey W. Tyner et al.   NATURE

TET2 coactivates gene expression through demethylation of enhancers

(2018) Lu Wang et al.   Science Advances

Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells

(2017) Feng Pan et al.   Nature Communications

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

(2016) C. Elena et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Exploring genomic alteration in pediatric cancer using ProteinPaint

(2016) Xin Zhou et al.   NATURE GENETICS

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

(2016) Jane Merlevede et al.   Nature Communications

Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance

(2016) M M Patnaik et al.   Blood Cancer Journal

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia

(2016) M M Patnaik et al.   Blood Cancer Journal

TET2 Regulates Mast Cell Differentiation and Proliferation through Catalytic and Non-catalytic Activities

(2016) Sara Montagner et al.   Cell Reports

Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome

(2015) Mrinal M. Patnaik et al.   AMERICAN JOURNAL OF HEMATOLOGY

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study

(2014) Emnet A. Wassie et al.   AMERICAN JOURNAL OF HEMATOLOGY

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia

(2014) E. Padron et al.   BLOOD

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients

(2014) M M Patnaik et al.   LEUKEMIA

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

(2013) O. Odejide et al.   BLOOD

Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation

(2013) Lulu Hu et al.   CELL

TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS

(2013) Rachel Deplus et al.   EMBO JOURNAL

Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma

(2013) F. Asmar et al.   HAEMATOLOGICA

Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

(2013) Raphaël Itzykson et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

(2013) F Traina et al.   LEUKEMIA

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine

(2013) A Valencia et al.   LEUKEMIA

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Deciphering Signatures of Mutational Processes Operative in Human Cancer

(2013) Ludmil B. Alexandrov et al.   Cell Reports

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

(2013) Y. Saunthararajah   Hematology-American Society of Hematology Education Program

Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters

(2012) F. Lemonnier et al.   BLOOD

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells

(2012) Hiroyoshi Kunimoto et al.   Scientific Reports

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

(2011) Z. Li et al.   BLOOD

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

(2011) Cyril Quivoron et al.   CANCER CELL

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

(2011) V Grossmann et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity

(2011) Kristine Williams et al.   NATURE

Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice

(2011) M. Ko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA

(2011) Y.-F. He et al.   SCIENCE

Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine

(2011) S. Ito et al.   SCIENCE

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

(2010) A. E. Smith et al.   BLOOD

Cytogenetic risk stratification in chronic myelomonocytic leukemia

(2010) E. Such et al.   HAEMATOLOGICA

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

(2010) Alexander Kohlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

(2010) Shinsuke Ito et al.   NATURE

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

(2009) O. Kosmider et al.   HAEMATOLOGICA

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine

(2008) Carlo Stresemann et al.   INTERNATIONAL JOURNAL OF CANCER